中国肿瘤临床与康杂志体腔循环灌注热化疗治疗恶性腹水临床研究.docVIP

中国肿瘤临床与康复 体腔循环灌注热化疗治疗恶性腹水的临床研究 作者单位：030001 山西省太原市解放军264医院肿瘤科（吴铁鹰、张峻青、武智刚、冯燕国、陈静、韩小龙）：山西省太原市解放军264医院统计室（刘永兰） [摘要] 目的 观察体外循环热灌注化疗与腹腔化疗治疗恶性腹水的疗效及副反应。方法：恶性腹水62例，同期分为治疗组及对照组，治疗组30例，采用TRL-2000体腔循环热化疗系统（哈尔滨宇航科技生产）行腹腔热疗,腹腔内温度达41-430C，给予顺铂60-80mg、地塞米松10mg注入腹腔, 体腔循环持续60分；对照组32例给予腹腔注入顺铂60-80mg。二组均2次/周，行二周。结果：治疗组：有效率90.0%（27/30）,KPS改善80.0%（24/30）；对照组：有效率43.7%（14/32）,KPS改善40.6%（13/32）；结论：体腔循环灌注热化疗治疗恶性腹水疗效好，生活质量提高较明显，患者可以耐受副作用。 [关健词] 恶性腹水 热灌注化疗 顺铂 通信作者；吴铁鹰，Email：wty02@ 030001 山西省太原市桥东街中段解放军264医院肿瘤科吴铁鹰 吴铁鹰、男、1963年11月生，山西太原人、学士学位、副主医师。现任北京军区264医院肿瘤科主任、北京军区肿瘤专业委员会主任委员。 Malignant seroperitoneum treated by abdominal hyperthermic perfusion with intraperitoneal chemotherapy. Wu Tie-ying, ZHANG Jun-qing, LIU Yong-lan, WU Zhi-gang, FENG Yan-guo,CHEN-Jin, HAN Xiao-long. Department of Oncology, the 264th hospital of PLA , Taiyuan 030001,China. Corresponding auther: Wu Tie-ying,Email: wtyO2@ [Abstract] OBJECTIVE：To observe efficacy and advervant of hyperthermic perfusion with intraperitoneal chemotherapy in patients with malignant seroperitoneum．METHOED：All patients were divided into two group randomly. Experimental group tunderwent abdominal hyperthermic perfusion and intraperitoneal chemotherapy with cisplatin. Control group was treated intraperitoneal chemotherapy through peritoneal pipe. Both were gived cisplatin 60-80mg twice a week. The responses of seroperitoneum and adverse events were observed．RESULTS：The total response rate of seroperitoneum experimental group was 90.0%， Karnofsky score was also elevated in experimental group80%,. contrast with 40.6% in control group CONCLUSIONS: Abdominal hyperthermic perfusion combined with intraperitoneal chemotherapy have good efficacy and safety in treating malignant seroperitoneum. KEY WORDS： malignant seroperitoneum；yperthermic perfusion； 恶性腹水是晚期肿瘤常见的并发症，其所致的呼吸急促、恶心、食欲减退和早饱、乏力、下肢水肿、活动受限等[1]，不仅加重了癌症的发展进程，同时严重影响了患者的生活质量[2]。引起恶性腹水的原发疾病以卵巢癌最常见，其它可由胃肠道肿瘤、胰腺癌、肝癌、子宫癌等引起。目前的恶性腹水治疗方法主要有：利尿剂、腹腔穿刺排液、腹腔穿刺放液、腹腔内化疗及免疫治疗等待。但疗效不尽如人意。热疗因其安